Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypertension and nephropathy.

George L Bakris1

  • 1Hypertension Clinical Research Center, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612, USA.

The American Journal of Medicine
|December 18, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factitious acidosis and severe hypoalbuminemia caused by unsuspected assay interference.

Clinical kidney journal·2021
Same author

Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.

British journal of pharmacology·2021
Same author

Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.

Circulation·2021
Same author

Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial.

Journal of the American Society of Nephrology : JASN·2021
Same author

Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects.

Nature reviews. Nephrology·2021
Same author

Longitudinal Blood Pressure Patterns and Chronic Kidney Disease Progression: An Evolving Paradigm.

Hypertension (Dallas, Tex. : 1979)·2021
Same journal

Mineralocorticoid Antagonists for Post-MI HFpEF: Plausible Biology Meets Low Residual Risk?

The American journal of medicine·2026
Same journal

GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

The American journal of medicine·2026
Same journal

Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

The American journal of medicine·2026
Same journal

Cave Canem - Beware of the Dog.

The American journal of medicine·2026
Same journal

Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

The American journal of medicine·2026
Same journal

Mesenteric panniculitis.

The American journal of medicine·2026
See all related articles

Many patients with hypertension and diabetes struggle to control blood pressure. Thiazolidinediones (TZDs) show promise in improving insulin resistance and vascular health, potentially reducing complications.

Area of Science:

  • Cardiology
  • Endocrinology
  • Nephrology

Background:

  • Hypertension and diabetes mellitus significantly increase cardiovascular and renal complication risks.
  • Most patients with both conditions do not achieve target systolic blood pressure (<130 mm Hg).
  • Renin-angiotensin system inhibitors and diuretics may help reduce blood pressure and slow nephropathy progression.

Purpose of the Study:

  • To explore the role of thiazolidinediones (TZDs) in managing hypertension and diabetes.
  • To investigate the vascular benefits of TZDs in type 2 diabetes patients.
  • To assess the impact of TZDs on glucose control, microalbuminuria, and hypertension.

Main Methods:

  • Review of recent studies on thiazolidinediones (TZDs) in type 2 diabetes.

Related Experiment Videos

  • Analysis of TZD effects on insulin resistance, vascular function, and blood pressure.
  • Examination of TZD association with microalbuminuria and hypertension development.

    • Main Results:

    • TZDs improve insulin resistance and offer vascular benefits like vasorelaxation and reduced inflammation.
    • These vascular effects are linked to blood pressure reduction and microalbuminuria prevention.
    • Early TZD use may aid glucose control and mitigate microalbuminuria and hypertension.

    Conclusions:

    • TZDs demonstrate potential benefits for patients with type 2 diabetes and hypertension.
    • Their use may improve glycemic control and reduce cardiovascular and renal complications.
    • Further research supports TZDs as a valuable therapeutic option in this patient group.